Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01737866 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency
A Phase 1 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01737866 is a Phase 1 study that has completed, run by Cytokinetics. The registered enrollment target is 13 participants.
The verdict
NCT01737866, a Phase 1 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
A phase 1, open-label study in subjects with normal renal function and subjects with various degrees of renal insufficiency, including patients with end-stage renal disease (ESRD) requiring hemodialysis. The primary objective is to evaluate the single-dose PK of AMG 423 in subjects with various degrees of renal insufficiency, including patients with end-stage renal disease requiring hemodialysis.
Interventions
- DRUG AMG 423
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01737866
The ClinicalTrials.gov registry entry for NCT01737866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AMG 423 is the first listed.
NCT01737866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01737866 about?
NCT01737866 is a clinical study titled "Pharmacokinetics Study of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency". A phase 1, open-label study in subjects with normal renal function and subjects with various degrees of renal insufficiency, including patients with end-stage renal disease (ESRD) requiring hemodialysis. The primary objective is to evaluate the single-dose PK of AMG 423 in subjects with various degr...
What is the current status of trial NCT01737866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2012-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01737866?
The interventions under investigation include: AMG 423 (DRUG).
Who is sponsoring clinical trial NCT01737866?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.